Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept

Nov 28, 2023

Press releases

Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept

Evaxion proudly announces the presentation of its novel precision vaccine concept at the 65th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, California, from December 9-12, 2023.

Preclinical efficacy of a cell division protein candidate gonococcal vaccine identified by artificial intelligence

Nov 27, 2023

Publications

Preclinical efficacy of a cell division protein candidate gonococcal vaccine identified by artificial intelligence

Publication: mBio
Authors: Sunita Gulati, Andreas Holm Mattsson, Sophie Schussek, Bo Zheng, Rosane B. DeOliveira, Jutamas Shaughnessy, Lisa A. Lewis, Peter A. Rice, Pär Comstedt, Sanjay Ram

Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy

Nov 15, 2023

Press releases

Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy

Evaxion presents for the first time its AI model designed to predict patient responses to cancer immunotherapy at the Biomarkers & Precision Oncology Europe conference in Berlin, Germany.

Presentation of Latest Confirmatory EVX01 Clinical Data with Key Opinion Leader Adnan Khattak

Nov 8, 2023

Presentations

Presentation of Latest Confirmatory EVX01 Clinical Data with Key Opinion Leader Adnan Khattak

In this presentation, Professor Adnan Khattak will set the scene by introducing participants to the medical field of malignant melanoma and the need that Evaxion’s personalized cancer vaccines is trying to meet. 

Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak

Nov 6, 2023

Press releases

Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak

Evaxion hosted an online webinar featuring Key Opinion Leader (KOL) and study’s Principal Investigator (PI), Professor Adnan Khattak. The webinar took place on November 8 at 11:30 a.m. EST

Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01

Oct 31, 2023

Press releases

Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01

Evaxion announces initial results from the EVX-01 Phase 2 clinical trial, confirming previous successful Phase 1 findings

New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented

Oct 26, 2023

Press releases

New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented

Evaxion is proud to announce that it will be presenting clinical readouts on its two personalized cancer vaccine trials at SITC’s 38th annual meeting, taking place in San Diego, California from November 1-5, 2023.

Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Oct 5, 2023

Press releases

Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Evaxion received a letter from the Listings Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”).

Connecting the dots: EDEN validation and partnerships

Sep 21, 2023

Presentations

Connecting the dots: EDEN validation and partnerships

Watch Evaxion founder Andreas Holm Mattson talk about EDEN validation and partnerships

Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea

Sep 20, 2023

Press releases

Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea

Evaxion announced a collaboration with Afrigen Biologics (Afrigen)

Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company 

Sep 18, 2023

Press releases

Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company 

Evaxion announced the initiation of a novel pipeline program, EVX-B3, an AI-designed vaccine candidate against an undisclosed bacterial pathogen.

Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development

Sep 11, 2023

Press releases

Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development

Evaxion has achieved a groundbreaking milestone in vaccine discovery with the validation of its AI-powered vaccine discovery platform, EDEN.

Evaxion Media kit

Subscribe to our Newsletter

Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.